Cannabis is now legal in 40 of 50 U.S. states for medical use, with recreational use legalized in 24 states. This has created a market for marijuana edibles, making gummies, chocolates and beverages more readily available to consumers, including minors. Reports of cannabis poisoning among children soared from 930 in 2009 to more than 22,000 in 2024 – and more than 75 percent of all cannabis poisonings involved children and teens in 2024, according to America's Poison Centers. （来源：CGTN） 随着大麻合法化与商业化席卷美国，大麻产品的 ...

Industry Overview - Cannabis stocks, including Canopy Growth and Aurora Cannabis, have seen a decline over the past five years despite initial popularity [1] - Recent regulatory changes, specifically President Trump's executive order rescheduling cannabis from Schedule 1 to Schedule 3, may provide new opportunities for the industry [3][4] Regulatory Changes - Cannabis is now classified as a Schedule 3 drug, indicating accepted medical benefits and lower potential for abuse compared to Schedule 1 and 2 substances [4] - This change could facilitate easier access to banking services and allow cannabis companies to deduct normal business expenses, potentially leading to increased revenue and profits [6] Company-Specific Insights - Canopy Growth has a market cap of $407 million, with a current price of $1.19 and a gross margin of 18.74% [5][6] - Aurora Cannabis has a market cap of $255 million, with a current price of $4.49 and a gross margin of -86.45% [8][9] - Despite the potential market size in the U.S., both companies face significant challenges, including federal illegality and competition [7][10] Market Challenges - Cannabis remains illegal at the federal level in the U.S., complicating interstate commerce for growers [7] - Aurora Cannabis lacks a retail or distribution presence in the U.S., which may hinder its ability to capitalize on market opportunities [7][9] - Canopy Growth, while having a subsidiary in the U.S., still faces similar federal and competitive challenges [10]

Core Insights - President Trump signed an executive order on December 18, 2025, to expedite the reclassification of marijuana, potentially making it a Schedule III drug, which would facilitate research and access for Medicare and Medicaid recipients [1][3] - The reclassification could lead to increased investment opportunities in the cannabis industry, which has experienced volatility [1][4] Industry Trends - Cannabis use among Americans aged 65 and older has significantly increased, rising from 4.8% in 2021 to 7% in 2023, marking a 46% increase [2] - The demand for cannabis is growing among seniors, particularly those with chronic diseases, indicating a shift in consumer demographics [6] Regulatory Environment - Marijuana is currently classified as a Schedule I substance, alongside drugs like heroin and LSD, but the executive order aims to change this classification to Schedule III, which includes drugs with recognized medical uses [3] - There is a complex legal landscape across states regarding marijuana use, with support for legalization rising from 36% in 2005 to 70% in 2023, reflecting changing consumer sentiment [5]

Core Viewpoint - The signing of the executive order by President Trump on December 18 aims to reclassify cannabis from a Schedule I controlled substance to a Schedule III controlled substance, which will facilitate medical research and exploration of cannabis's benefits and potential harms [1][3]. Group 1: Regulatory Changes - The reclassification will lower the barriers for medical research on cannabis, allowing it to be recognized for certain medical uses [3]. - Schedule III substances are defined as having a moderate to low risk of physical and psychological dependence, which includes some common medications like Tylenol with codeine [3]. - The executive order mandates the U.S. Attorney General to expedite the process of relaxing federal restrictions on cannabis, although no specific timeline is provided [3]. Group 2: Political and Industry Support - The cannabis industry has engaged in extensive lobbying efforts to encourage the Trump administration to ease cannabis regulations, receiving significant support from various political factions [4][5]. - The "American Rights and Reform Political Action Committee," backed by the cannabis industry, has made substantial donations to Trump's campaign, including $1 million to the "Make America Great Again" super PAC [5]. - Key executives from major cannabis companies have met with Trump to discuss the potential for job creation and the need for regulatory changes [6]. Group 3: Public Perception and Criticism - Critics warn that lowering the classification of cannabis may send a misleading message about its dangers, potentially normalizing its use among the public, especially youth [9]. - The cannabis industry is viewed as a multi-billion dollar sector, with increasing accessibility and potential for growth, despite ongoing federal restrictions [10].

Core Viewpoint - President Donald Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, significantly impacting the cannabis industry and leading to a surge in US cannabis stocks [1] Group 1: Executive Order Impact - The executive order directs federal agencies to change the classification of marijuana, which could lead to increased research and development opportunities within the cannabis sector [1] - This reclassification is expected to reduce regulatory burdens on cannabis companies, potentially enhancing their operational capabilities and market access [1] Group 2: Market Reaction - Following the announcement, US cannabis stocks experienced a sharp increase, indicating strong investor optimism regarding the future of the cannabis market [1] - The market response reflects a growing acceptance of cannabis and its potential for commercialization, which may attract more investment into the sector [1]

Core Insights - Tilray's stock price surged nearly 30% on Tuesday, reaching a high of $14.40, in anticipation of Donald Trump's executive order to reschedule cannabis into a lower drug classification [1] Company Impact - The significant increase in Tilray's stock price reflects investor optimism regarding potential regulatory changes that could benefit the cannabis industry [1] Industry Implications - The rescheduling of cannabis could lead to broader market acceptance and increased investment in the cannabis sector, potentially transforming the landscape for cannabis-related companies [1]

Core Viewpoint - The U.S. government is considering reclassifying marijuana as a "lower-risk drug," which could significantly benefit the multi-billion dollar cannabis industry by easing research restrictions [1][3]. Group 1: Government Actions and Implications - President Trump indicated that the government is contemplating the reclassification of marijuana to facilitate research, which has been hindered under its current classification as a Schedule I drug [3]. - The reclassification would not legalize marijuana or decriminalize its use but would lower research barriers and enhance the legal operating environment for businesses in the cannabis sector [4]. - The potential shift in regulation aligns with a broader trend of states legalizing medical and recreational marijuana, reflecting changing societal attitudes towards cannabis [5]. Group 2: Industry Impact and Lobbying - The cannabis industry has seen significant lobbying efforts, with over $22.4 million spent on political lobbying related to cannabis products from 2018 to 2022 [5]. - The push for legalization and reclassification is closely tied to financial interests and political lobbying, indicating a strong influence of interest groups in shaping cannabis policy [5]. - Despite the potential benefits of reclassification, concerns remain regarding the health impacts of marijuana use, including addiction and mental health issues [4].

Core Insights - Tilray's stock, along with shares of other cannabis companies, experienced a significant increase following reports suggesting that President Trump may consider reclassifying marijuana as a less dangerous drug [1] Group 1: Market Reaction - The stock prices of Tilray and other cannabis firms soared, indicating a positive market sentiment driven by potential regulatory changes [1] - Investors are optimistic about the implications of reclassification on the cannabis industry, which could lead to increased market opportunities [1] Group 2: Regulatory Environment - The potential move by President Trump to reclassify marijuana could signify a shift in the regulatory landscape for cannabis, impacting both current and future investments in the sector [1] - Reclassification may reduce legal barriers and enhance the legitimacy of cannabis products, fostering growth within the industry [1]

Core Viewpoint - The U.S. government is expected to significantly relax federal regulations on cannabis, aligning its oversight with that of certain common prescription pain medications and other drugs [1][3]. Group 1: Regulatory Changes - President Trump discussed plans to reclassify cannabis during a call with House Speaker Mike Johnson, aiming to ease access restrictions through an upcoming executive order [1][3]. - The reclassification would not legalize cannabis or decriminalize it but would lower research barriers and enhance the legal operating baseline for businesses [3]. Group 2: Political Dynamics - Speaker Johnson expressed skepticism about the reclassification, citing various studies and data against it, while industry executives present during the call attempted to counter his arguments [3]. - The push for cannabis legalization at the federal level is gaining momentum, influenced by interest groups that have spent over $22.4 million on political lobbying related to cannabis from 2018 to 2022 [4]. Group 3: Societal Implications - The increasing legalization of cannabis reflects deeper societal issues related to drug use and abuse in the U.S., with concerns that the normalization of cannabis could exacerbate substance abuse problems [4].

Core Insights - Curaleaf is expanding its operations by opening a new dispensary in Cape Canaveral, Florida, marking its 70th outlet in the state, which is significant given Florida's large population and GDP ranking [2][3] - The stock price of Curaleaf increased by 9% following the announcement of the new dispensary and a new marijuana reform resolution in Congress, indicating positive investor sentiment [1][5] - The potential for Florida to transition from a medical marijuana market to a recreational one is gaining traction, which could significantly enhance market opportunities for companies like Curaleaf [3][4] Company Developments - Curaleaf has opened its 70th dispensary in Florida, a state that ranks third in population and fifth in GDP in the U.S., highlighting the company's growth strategy in a key market [2] - The company's stock performance reflects investor optimism, with a notable increase of 9% in a single trading session [1][5] Industry Context - The marijuana industry is witnessing ongoing efforts for legalization, with a new resolution submitted by Democrats in the U.S. House of Representatives aimed at promoting equity in the industry and influencing international drug policy [4][7] - Despite the positive developments, the overall impact on struggling companies like Curaleaf may remain limited until full legalization occurs, indicating a cautious outlook for the industry [6][7]